Post‑Transplant, Epstein‑Barr Virus DNA, Quantitative Real‑Time PCR, Plasma
Also known as: PTxplnt, Specialized, Txplnt, Services, Quest Advanced
Use
Monitoring EBV DNA levels by quantitative PCR in patients at risk of EBV‑associated lymphoproliferative disorders may allow timely recognition of virus reactivation and permit installment of antiviral treatment. Reportable Range is 200‑2,000,000 copies/mL (2.30‑6.30 log copies/mL).
Special Instructions
Specimen requirements: Preferred: 1 mL (0.5 mL minimum) whole blood collected in an EDTA (lavender‑top) tube or Serum or CSF collected in a sterile, plastic, leak‑proof container. Acceptable: Bronchoalveolar lavage (BAL). Avoid sodium or lithium heparin tubes. Whole blood frozen is unacceptable. Transport refrigerated; stability: room temp 48 h, refrigerated 8 days; whole blood frozen unacceptable; serum, CSF, BAL frozen 30 days. Setup daily; report available in 1 day.
Limitations
Not provided.
FDA Approved
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
1 mL (0.5 mL minimum)
Minimum Volume
0.5 mL
Container
EDTA (lavender‑top) tube
Causes for Rejection
Sodium or lithium heparin tube; whole blood frozen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 8 days |
| Frozen | Unacceptable |